Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 17/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22616028 | 0.86 | HTR1A (0.41) | NAMPT | |
| SCHEMBL20642053 | 0.85 | GPR119 (0.50) | GPR119NAMPTCYP2C9 | |
| SCHEMBL29607711 | 0.83 | NAMPT (0.47) | GPR119NAMPTCYP2C9 | |
| SCHEMBL17687885 | 0.80 | NAMPT (0.45) | GPR119NAMPT | |
| SCHEMBL27431212 | 0.79 | GPR119 (0.50) | GPR119NAMPTCYP2C9 | |
| SCHEMBL29608243 | 0.78 | NAMPT (0.46) | GPR119NAMPTCYP2C9 | |
| SCHEMBL30328847 | 0.78 | IDH1 (0.50) | GPR119NAMPT | |
| SCHEMBL30328384 | 0.76 | IDH1 (0.49) | GPR119NAMPT | |
| SCHEMBL29607140 | 0.76 | NAMPT (0.53) | GPR119NAMPTCYP2C9 | |
| SCHEMBL28673618 | 0.76 | POLB (0.45) | OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | GPR119 113/4885NAMPT 1156/4885CYP2C9 3369/4885 |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA2 | GPR119 156/4885NAMPT 937/4885CYP2C9 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.